James I Healy

Bio

im joined Sofinnova in 2000 as a General Partner and has over 20 years of experience in biomedical research, development and finance. He specializes in financing late stage drug development and pharmaceutical spin offs. Jim invests in both traditional private equity and small-cap public financings, and serves or has served on the board of companies in Belgium, Ireland, Switzerland and the United States. As a venture capitalist, Jim was an active early investor and board member for six portfolio companies that were acquired, five initial public offerings and one of the top recent PIPE financings. Prior to Sofinnova, Jim worked at Bayer AG (Miles) in blood product manufacturing, at Sanderling, and advised the research and discovery group at ISTA Pharmaceuticals (ISTA). He is currently a member of the BIO-NVCA working group. He also performed Neuroscience research in the Department of Pathology at the University of Virginia School of Medicine and received a prestigious Bursary Award from the Novartis Foundation. Jim authored or co-authored thirteen peer reviewed articles and invited reviews, including three papers published in Nature. He currently serves on the board of directors of Amarin (AMRN), Anthera (ANTH), Cebix, Durata, Intermune (ITMN) and Sorbent. He is also the Chairman of the Board at Hyperion and Kalobios. Previously, he served as a board member of Cellective (acquired by AstraZeneca), Cotherix (CTRX, acquired by Actelion), Movetis (MOVE, acquired by Shire), Novacea (NOVC, acquired by Transcept), Preglem (acquired by Richter) and Prestwick (acquired by Biovail). Previously, Jim served as a member of the Executive Board of the College of Letters and Science at the University of California at Berkeley and taught a course on entrepreneurship at Stanford University. He has financed and been a board member of five companies which received either FDA or EMA approval to market their drugs. Jim graduated with a BA in Molecular Biology and a BA in Scandinavian Studies from the University of California at Berkeley where he graduated with Honors, Distinction in General Scholarship and received the Departmental Citation. Jim received his MD and PhD in Immunology from Stanford University School of Medicine through the NIH Medical Scientist Training Program and had the distinction of being named a Beckman Scholar.